Annual report pursuant to Section 13 and 15(d)

Licenses Acquired (Narrative) (Details)

v3.21.1
Licenses Acquired (Narrative) (Details)
1 Months Ended 12 Months Ended 24 Months Ended
Dec. 17, 2020
USD ($)
Milestone
Dec. 17, 2019
USD ($)
Milestone
agreement
shares
Oct. 15, 2015
USD ($)
Sep. 30, 2015
USD ($)
shares
May 11, 2015
USD ($)
$ / shares
shares
Mar. 31, 2015
USD ($)
Milestone
Dec. 31, 2019
USD ($)
$ / shares
installment
Jun. 30, 2019
USD ($)
Mar. 31, 2017
USD ($)
Oct. 31, 2016
USD ($)
Milestone
shares
May 31, 2016
USD ($)
Dec. 31, 2015
Milestone
Apr. 30, 2015
USD ($)
Milestone
Mar. 31, 2015
USD ($)
Feb. 28, 2015
USD ($)
Dec. 31, 2020
USD ($)
Milestone
Dec. 31, 2019
USD ($)
$ / shares
Dec. 31, 2020
USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Research and development - licenses acquired                               $ 2,834,000 $ 6,090,000  
Research and Development Expense                               64,109,000 81,326,000  
Product revenue, net                               44,531,000 34,921,000  
Maintenance fees paid                               50,000 25,000  
Licensing Agreements [Member] | Adimab Llc Collaboration Agreement [Member] | Achievement of Each Milestones [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Payments of milestones     $ 7,100,000                              
Licensing Agreements [Member] | Adimab Llc Collaboration Agreement [Member] | Upon Various Filings for Regulatory Approvals [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Payments of milestones     $ 4,800,000                              
Aevitas [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Research and development - licenses acquired                               62,000 0  
Aevitas [Member] | Licensing Agreements [Member] | University of Massachusetts [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Research and development - licenses acquired                               100,000    
Number of net sales milestones | Milestone 4                                  
Aevitas [Member] | Licensing Agreements [Member] | University of Massachusetts [Member] | Achievement of Each Milestones [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Payments of milestones $ 1,000,000.0                                  
Aevitas [Member] | Licensing Agreements [Member] | University of Massachusetts [Member] | Achievement of Certain Sales Milestones [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Payments of milestones $ 4,000,000.0                                  
Avenue [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Research and development - licenses acquired                               0 1,000,000  
Avenue [Member] | Licensing Agreements [Member] | IV Tramadol [Member] | Revogenex Ireland Ltd [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Upfront fees payment                             $ 3,000,000.0      
Research and development - licenses acquired                               0 1,000,000.0  
Payments of milestones                               3,000,000.0    
Baergic [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Research and development - licenses acquired                               11,000 3,290,000  
Baergic [Member] | Licensing Agreements [Member] | AstraZeneca [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Research and development - licenses acquired                               9,000 0  
Number of license agreement | agreement   2                                
Baergic [Member] | Licensing Agreements [Member] | Cincinnati Children's Hospital Medical Center [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Upfront fees payment   $ 200,000                                
Research and development - licenses acquired                               2,000 0  
Number of net sales milestones | Milestone   4                                
Number of development milestones | Milestone   2                                
Payments of milestones   $ 21,000,000.0                                
Common shares issued (in shares) | shares   624,922                                
Reimbursement of past patent expenses   $ 30,000                                
Payment of upfront licensing fee   $ 6,500,000                                
Stock Issued During Period, Shares, New Issues | shares   624,922                                
Percentage of common shares issued (in percent)   5.00%                                
Amount of net of debt utilized                                 $ 100,000  
Baergic [Member] | Licensing Agreements [Member] | Cincinnati Children's Hospital Medical Center [Member] | Discount for Lack of Marketability [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Common Shares, measurement input             0.446                   0.446  
Baergic [Member] | Licensing Agreements [Member] | Cincinnati Children's Hospital Medical Center [Member] | Measurement Input Weighted Average Cost of Capital [ Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Common Shares, measurement input             0.205                   0.205  
Baergic [Member] | Licensing Agreements [Member] | Cincinnati Children's Hospital Medical Center [Member] | Share Price [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Common Shares, measurement input | $ / shares             0.029                   0.029  
Baergic [Member] | Licensing Agreements [Member] | Maximum [Member] | AstraZeneca [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Issuance of anti-dilution protection of shares   $ 15,000,000.0                                
Baergic [Member] | Licensing Agreements [Member] | AZ License [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Amount of net of debt utilized                                 $ 100,000  
Baergic [Member] | Licensing Agreements [Member] | AZ License [Member] | Share Price [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Common Shares, measurement input | $ / shares             0.029                   0.029  
Baergic [Member] | Licensing Agreements [Member] | AZ License [Member] | AstraZeneca [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Upfront fees payment   $ 3,000,000.0                                
Number of net sales milestones | Milestone   3                                
Common shares issued (in shares) | shares   2,492,192                                
Stock Issued During Period, Shares, New Issues | shares   2,492,192                                
Percentage of common shares issued (in percent)   19.95%                                
Baergic [Member] | Licensing Agreements [Member] | AZ License [Member] | AstraZeneca [Member] | Achievement of Each Milestones [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Payments of milestones   $ 75,000,000                                
Baergic [Member] | Licensing Agreements [Member] | AZ License [Member] | AstraZeneca [Member] | Achievement of Certain Sales Milestones [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Payments of milestones   130,000,000                                
Baergic [Member] | Licensing Agreements [Member] | AZ License [Member] | AstraZeneca [Member] | Discount for Lack of Marketability [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Common Shares, measurement input             0.446                   0.446  
Baergic [Member] | Licensing Agreements [Member] | AZ License [Member] | AstraZeneca [Member] | Measurement Input Weighted Average Cost of Capital [ Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Common Shares, measurement input             0.205                   0.205  
Baergic [Member] | Licensing Agreements [Member] | AZ License [Member] | Maximum [Member] | AstraZeneca [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Issuance of anti-dilution protection of shares   $ 75,000,000                                
Cellvation [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Research and development - licenses acquired                               1,000 $ 0  
Cellvation [Member] | Licensing Agreements [Member] | Initial TBI License [Member] | University of Texas [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Upfront fees payment                   $ 300,000                
Common shares issued (in shares) | shares                   500,000                
Stock Issued During Period, Shares, New Issues | shares                   500,000                
Percentage of common shares issued (in percent)                   5.00%                
Cellvation [Member] | Licensing Agreements [Member] | Initial TBI License [Member] | University of Texas [Member] | Development of Adult Indications [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Number of development milestones | Milestone                   9                
Payments of milestones                   $ 6,200,000                
Cellvation [Member] | Licensing Agreements [Member] | Initial TBI License [Member] | University of Texas [Member] | Development of Pediatric Indications [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Number of development milestones | Milestone                   8                
Payments of milestones                   $ 6,000,000.0                
Cellvation [Member] | Licensing Agreements [Member] | Initial TBI License [Member] | Minimum [Member] | University of Texas [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Additional Minimum Annual Royalty Payable                   50,000                
Cellvation [Member] | Licensing Agreements [Member] | Initial TBI License [Member] | Maximum [Member] | University of Texas [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Additional Minimum Annual Royalty Payable                   200,000                
Cellvation [Member] | Licensing Agreements [Member] | Second TBI License [Member] | University of Texas [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Upfront fees payment                   50,000                
Research and development - licenses acquired                               $ 1,000 0  
Payments of milestones                   300,000                
Common shares issued, value                                 500,000  
Minimum Annual Royalty Payable                   $ 100,000                
Checkpoint [Member] | Licensing Agreements [Member] | Dana Farber Cancer Institute [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Upfront fees payment         $ 1,000,000.0                          
Common shares issued, value       $ 600,000 $ 32,500                          
Common shares issued (in shares) | shares       136,830 500,000                          
Shares issued, price per share | $ / shares         $ 0.065                          
Issuance of anti-dilution protection of shares         $ 10,000,000.0                          
Stock Issued During Period, Shares, New Issues | shares       136,830 500,000                          
Annual Maintenance Fee Payable       $ 50,000                            
Checkpoint [Member] | Licensing Agreements [Member] | Dana Farber Cancer Institute [Member] | Checkpoint [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners         5.00%                          
Checkpoint [Member] | Licensing Agreements [Member] | Dana Farber Cancer Institute [Member] | Achievement of Each Milestones [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Issuance of anti-dilution protection of shares       21,500,000                            
Checkpoint [Member] | Licensing Agreements [Member] | Dana Farber Cancer Institute [Member] | Achievement of Certain Sales Milestones [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Payments of milestones       $ 60,000,000.0                            
Checkpoint [Member] | Licensing Agreements [Member] | NeuPharma, Inc. [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Payment of upfront licensing fee                           $ 1,000,000.0        
Checkpoint [Member] | Licensing Agreements [Member] | NeuPharma, Inc. [Member] | Achievement of Certain Sales Milestones [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Payments of milestones                           40,000,000        
Checkpoint [Member] | Licensing Agreements [Member] | NeuPharma, Inc. [Member] | Completion of Clinical Development Milestones [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Payments of milestones                           40,000,000.0        
Checkpoint [Member] | Licensing Agreements [Member] | NeuPharma, Inc. [Member] | Regulatory Approvals to Commercialize the Products [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Payments of milestones                           $ 22,500,000        
Checkpoint [Member] | Licensing Agreements [Member] | Jubilant Biosys Ltd [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Upfront fees payment                     $ 2,000,000.0              
Checkpoint [Member] | Licensing Agreements [Member] | Jubilant Biosys Ltd [Member] | Achievement of Certain Sales Milestones [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Payments of milestones                     89,000,000.0              
Checkpoint [Member] | Licensing Agreements [Member] | Jubilant Biosys Ltd [Member] | Achievement of Certain Preclinical, Clinical Development, and Regulatory Milestones [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Payments of milestones                     89,000,000.0              
Checkpoint [Member] | Licensing Agreements [Member] | Jubilant Biosys Ltd [Member] | Regulatory Approvals to Commercialize the Products [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Payments of milestones                     $ 59,500,000              
Checkpoint [Member] | Licensing Agreements [Member] | Collaborative Agreements with TGTX [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Percentage of IND enabling costs and patent expenses                               50.00%    
Checkpoint [Member] | Licensing Agreements [Member] | Collaborative Agreements with TGTX [Member] | Upon Various Filings for Regulatory Approvals [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Payments of milestones                               $ 87,200,000    
Checkpoint [Member] | Licensing Agreements [Member] | Collaborative Agreements with TGTX [Member] | Completion of Clinical Development Milestones [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Payments of milestones                               25,500,000    
Checkpoint [Member] | Licensing Agreements [Member] | Collaborative Agreements with TGTX [Member] | Achievement of Five Regulatory Approvals [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Payments of milestones                               61,700,000    
Checkpoint [Member] | Licensing Agreements [Member] | Collaborative Agreements with TGTX [Member] | Achievement of Three Sales Milestones [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Payments of milestones                               89,000,000.0    
Checkpoint [Member] | Licensing Agreements [Member] | Collaborative Agreements with TGTX [Member] | Dana Farber Cancer Institute [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Revenue from collaboration agreement                               1,000,000.0 1,600,000  
Additional Annual License fee               $ 1,000,000.0                    
Checkpoint [Member] | Licensing Agreements [Member] | Collaborative Agreements with TGTX [Member] | Dana Farber Cancer Institute [Member] | Completion of Clinical Development Milestones [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Payments of milestones               8,400,000                    
Checkpoint [Member] | Licensing Agreements [Member] | Collaborative Agreements with TGTX [Member] | Dana Farber Cancer Institute [Member] | Upon the Twelfth Patient Dosed in a Phase 1 Clinical Study [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Payments of milestones                               925,000    
Checkpoint [Member] | Licensing Agreements [Member] | Collaborative Agreements with TGTX [Member] | Jubilant Biosys Ltd [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Upfront fees payment                               $ 1,000,000.0    
Number of development milestones | Milestone                               3    
Revenue from collaboration agreement                               $ 100,000 100,000 $ 0
Checkpoint [Member] | Licensing Agreements [Member] | Collaborative Agreements with TGTX [Member] | Jubilant Biosys Ltd [Member] | Achievement of Five Regulatory Approvals [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Number Of Regulatory Milestones | Milestone                               5    
Checkpoint [Member] | Licensing Agreements [Member] | Collaborative Agreements with TGTX [Member] | Jubilant Biosys Ltd [Member] | Achievement of Three Sales Milestones [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Number of net sales milestones | Milestone                               3    
Checkpoint [Member] | Licensing Agreements [Member] | Anti-PD-L1 [Member] | Collaborative Agreements with TGTX [Member] | Dana Farber Cancer Institute [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Upfront fees payment               500,000                    
Checkpoint [Member] | Licensing Agreements [Member] | Anti-PD-L1 [Member] | Collaborative Agreements with TGTX [Member] | Dana Farber Cancer Institute [Member] | Achievement of Certain clinical Development, Regulatory and First Commercial Sale milestones [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Payments of milestones               27,600,000                    
Checkpoint [Member] | Licensing Agreements [Member] | Anti-PD-L1 [Member] | Collaborative Agreements with TGTX [Member] | Dana Farber Cancer Institute [Member] | First Commercial Sales in Specified Territories [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Payments of milestones               19,200,000                    
Checkpoint [Member] | Licensing Agreements [Member] | Anti-GITR Antibody [Member] | Collaborative Agreements with TGTX [Member] | Dana Farber Cancer Institute [Member] | Achievement of Certain Sales Milestones [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Payments of milestones                               $ 60,000,000.0    
Checkpoint [Member] | Licensing Agreements [Member] | Anti-GITR Antibody [Member] | Collaborative Agreements with TGTX [Member] | Dana Farber Cancer Institute [Member] | Achievement of Certain clinical Development, Regulatory and First Commercial Sale milestones [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Payments of milestones               21,500,000                    
Checkpoint [Member] | Licensing Agreements [Member] | Anti-GITR Antibody [Member] | Collaborative Agreements with TGTX [Member] | Dana Farber Cancer Institute [Member] | Completion of Clinical Development Milestones [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Payments of milestones               $ 7,000,000.0                    
Checkpoint [Member] | Licensing Agreements [Member] | Anti-GITR Antibody [Member] | Collaborative Agreements with TGTX [Member] | Dana Farber Cancer Institute [Member] | First Commercial Sales in Specified Territories [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Payments of milestones                               14,500,000    
Helocyte [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Research and development - licenses acquired                               0 450,000  
Helocyte [Member] | Licensing Agreements [Member] | National Institute of Allergy and Infectious Disease (NIAD) [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Upfront fees payment             $ 500,000                      
Research and development - licenses acquired                               0 500,000  
Minimum Annual Royalty Payable             $ 55,000                      
Payment Of Upfront Fees, Number Of Installments | installment             3                      
Helocyte [Member] | Licensing Agreements [Member] | National Institute of Allergy and Infectious Disease (NIAD) [Member] | Achievement of Four Development Milestones [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Additional Minimum Annual Royalty Payable             $ 1,050,000                      
Helocyte [Member] | Licensing Agreements [Member] | National Institutes of Health ("NIH") [Member] | Achievement of Four Development Milestones [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Number of development milestones | Milestone                       4            
Helocyte [Member] | Licensing Agreements [Member] | City of Hope (COH) [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Upfront fees payment                         $ 45,000          
Helocyte [Member] | Licensing Agreements [Member] | Triplex [Member] | City of Hope (COH) [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Upfront fees payment           $ 200,000                        
Helocyte [Member] | Licensing Agreements [Member] | Triplex [Member] | City of Hope (COH) [Member] | Achievement of Each Milestones [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Payments of milestones           $ 7,500,000                        
Helocyte [Member] | Licensing Agreements [Member] | Triplex [Member] | City of Hope (COH) [Member] | Achievement of Certain Sales Milestones [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Number of net sales milestones | Milestone           3                        
Payments of milestones           $ 26,000,000.0                        
Helocyte [Member] | Licensing Agreements [Member] | Triplex [Member] | City of Hope (COH) [Member] | Financial Milestones [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Number of net sales milestones | Milestone           3                        
Number of development milestones | Milestone           2                        
Payments of milestones           $ 3,700,000                        
Helocyte [Member] | Licensing Agreements [Member] | Pentameter [Member] | City of Hope (COH) [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Research and development - licenses acquired                               0 0  
Helocyte [Member] | Licensing Agreements [Member] | Pentameter [Member] | City of Hope (COH) [Member] | Achievement of Four Development Milestones [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Number of development milestones | Milestone                         4          
Payments of milestones                         $ 5,500,000          
Helocyte [Member] | Licensing Agreements [Member] | Pentameter [Member] | City of Hope (COH) [Member] | Achievement of Three Sales Milestones [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Number of net sales milestones | Milestone                         3          
Payments of milestones                         $ 26,000,000.0          
Helocyte [Member] | Licensing Agreements [Member] | Pentameter [Member] | City of Hope (COH) [Member] | First Marketing Approval [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Minimum Annual Royalty Payable                         $ 750,000          
Cyprium [Member] | Licensing Agreements [Member] | National Institutes of Health ("NIH") [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Upfront fees payment                 $ 100,000                  
Research and development - licenses acquired                               $ 0 $ 0  
Cyprium [Member] | Licensing Agreements [Member] | National Institutes of Health ("NIH") [Member] | Achievement of Certain Sales Milestones [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Payments of milestones                 1,000,000                  
Cyprium [Member] | Licensing Agreements [Member] | National Institutes of Health ("NIH") [Member] | Completion of Clinical Development Milestones [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Payments of milestones                 1,700,000                  
Cyprium [Member] | Licensing Agreements [Member] | National Institutes of Health ("NIH") [Member] | Redeems a PRV [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Payments of milestones                 $ 15,000,000                  
Cyprium [Member] | Licensing Agreements [Member] | National Institutes of Health ("NIH") [Member] | First PRV Sold [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Sales royalties (as a percent)                 20.00%                  
Cyprium [Member] | Licensing Agreements [Member] | National Institutes of Health ("NIH") [Member] | Second PRV Sold [Member]                                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                    
Sales royalties (as a percent)                 15.00%